Kreitzer Anatol 4

What Happened
Anatol Kreitzer, Chief Discovery Officer of MapLight Therapeutics (MPLT), was granted equity awards on February 5, 2026 totaling 30,475 units (6,020 shares and 24,455 derivative RSUs). The reported acquisition price for both entries is $0.00, meaning no cash was paid. The 24,455 units are reported as derivative RSUs (contingent rights to receive shares upon vesting).

Key Details

• Transaction date: 2026-02-05; Filing date: 2026-02-09 (filed four days after the grant; note this exceeds the typical 2-business-day Form 4 deadline).
• Grants reported: 6,020 shares @ $0.00 (direct award) and 24,455 RSUs @ $0.00 (derivative). Total awarded = 30,475 units.
• Shares owned after transaction: not specified in the provided excerpt of the filing.
• Footnotes from the filing:
  • F1: The RSU award vests 1/4 on Jan 1, 2027, then 1/16 on each subsequent April 1, July 1, Oct 1 and Jan 1 thereafter, subject to continued service.
  • F2: Each RSU represents a contingent right to receive one share of common stock upon vesting.
  • F3: Describes an option vesting schedule (1/4 on Feb 5, 2027, then 1/48 monthly thereafter); included in the filing footnotes but separate from the RSU entries above.
• Transaction type code: A = Award/Grant.

Context
These are equity awards (RSUs and a direct share award), not open-market purchases or sales. RSUs are contingent — they convert into shares only as they vest per the schedule above — so this grant does not increase immediately tradeable shares. Grants to executives are common compensation and do not by themselves indicate intent to buy or sell stock.